Literature DB >> 22105884

[Ischemic stroke patients following intravenous thrombolysis. Outcome in a regional stroke center].

G Pawlik1, B Wagner, M Schabet.   

Abstract

BACKGROUND: We wanted to compare the outcome following IV thrombolysis in our patients with ischemic stroke with the outcome reported from the phase 3 registration trials and other large trials. PATIENTS AND METHODS: From January 2008 through December 2009 we treated 225 patients with ischemic stroke with IV thrombolysis. Retrospectively, we analyzed their clinical data upon admission, during their stay, and upon discharge with special reference to eligibility criteria for IV thrombolysis, symptomatic hemorrhage, and clinical outcome.
RESULTS: The average age of the patients was 74 years, with 34% being older than 80 years. The median time between stroke onset and initiation of treatment was 112 min. The initial median NIHSS was 11 points (Rankin score  ≥ 4 in 79% of patients). The rate of symptomatic hemorrhage was 3%. The median follow-up was 14 days. At the end of the observation period, clinical symptoms had improved in 73% of patients (Rankin score  ≤ 2 in 45% of patients). The mortality rate was 12%. In 55% of patients, IV thrombolysis was off label (age  > 80 years in 34% of patients).
CONCLUSION: The clinical results of IV thrombolysis in our stroke center are similar to the outcome reported from the registration trials and larger clinical series although we treated off label in more than half of the patients. Even larger studies have since shown that the age limit under 80 years for patients is not reasonable. The eligibility criteria should be adapted to reality at this point.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22105884     DOI: 10.1007/s00115-011-3399-z

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  13 in total

1.  Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke.

Authors:  W M Clark; S Wissman; G W Albers; J H Jhamandas; K P Madden; S Hamilton
Journal:  JAMA       Date:  1999-12-01       Impact factor: 56.272

2.  Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study.

Authors:  G W Albers; V E Bates; W M Clark; R Bell; P Verro; S A Hamilton
Journal:  JAMA       Date:  2000-03-01       Impact factor: 56.272

3.  Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study.

Authors:  Nils Wahlgren; Niaz Ahmed; Antoni Dávalos; Gary A Ford; Martin Grond; Werner Hacke; Michael G Hennerici; Markku Kaste; Sonja Kuelkens; Vincent Larrue; Kennedy R Lees; Risto O Roine; Lauri Soinne; Danilo Toni; Geert Vanhooren
Journal:  Lancet       Date:  2007-01-27       Impact factor: 79.321

4.  Thrombolytic therapy for acute ischaemic stroke in octogenarians: selection by magnetic resonance imaging improves safety but does not improve outcome.

Authors:  P A Ringleb; Ch Schwark; M Köhrmann; S Külkens; E Jüttler; W Hacke; P D Schellinger
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-10-20       Impact factor: 10.154

5.  Tissue plasminogen activator for acute ischemic stroke.

Authors: 
Journal:  N Engl J Med       Date:  1995-12-14       Impact factor: 91.245

6.  Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke.

Authors:  Werner Hacke; Markku Kaste; Erich Bluhmki; Miroslav Brozman; Antoni Dávalos; Donata Guidetti; Vincent Larrue; Kennedy R Lees; Zakaria Medeghri; Thomas Machnig; Dietmar Schneider; Rüdiger von Kummer; Nils Wahlgren; Danilo Toni
Journal:  N Engl J Med       Date:  2008-09-25       Impact factor: 91.245

7.  Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators.

Authors:  W Hacke; M Kaste; C Fieschi; R von Kummer; A Davalos; D Meier; V Larrue; E Bluhmki; S Davis; G Donnan; D Schneider; E Diez-Tejedor; P Trouillas
Journal:  Lancet       Date:  1998-10-17       Impact factor: 79.321

8.  Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS)

Authors:  W Hacke; M Kaste; C Fieschi; D Toni; E Lesaffre; R von Kummer; G Boysen; E Bluhmki; G Höxter; M H Mahagne
Journal:  JAMA       Date:  1995-10-04       Impact factor: 56.272

9.  Thrombolysis in patients older than 80 years with acute ischaemic stroke: Canadian Alteplase for Stroke Effectiveness Study.

Authors:  P N Sylaja; Robert Cote; Alastair M Buchan; Michael D Hill
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-02-27       Impact factor: 10.154

10.  Thrombolysis in very elderly people: controlled comparison of SITS International Stroke Thrombolysis Registry and Virtual International Stroke Trials Archive.

Authors:  Nishant K Mishra; Niaz Ahmed; Grethe Andersen; José A Egido; Perttu J Lindsberg; Peter A Ringleb; Nils G Wahlgren; Kennedy R Lees
Journal:  BMJ       Date:  2010-11-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.